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ABSTRACT
Objective: To replicate, using the Greek version of the 15D instrument,
the three-stage valuation procedure, using a sample of coronary artery
disease patients; to assess on a preliminary basis the psychometric
properties of the instrument in the Greek health-care environment; to
evaluate the health-related quality of life of patients with coronary artery
disease.
Methods: The generic instrument 15D was translated and culturally
adapted into the Greek language and setting. It was then administered
during October 2005 to May 2006 to 420 coronary artery disease
patients. The three-stage valuation procedure was employed and, with the
use of elicited preference weights, a single health-related quality of life
index score for the patients was derived. Scores were also calculated using
the original Finnish valuation system and compared with the previously
derived utilities. Sensitivity, reliability, and validity were assessed by
examining response distributions, ﬂoor and ceiling effects, item-scale
correlations, Cronbach’s alpha coefﬁcients, and hypothesized relation-
ships between sociodemographic variables and health-related quality of
life.
Results: The Greek valuation systematically generated higher 15D utilities
than the Finnish one. Nevertheless, the utilities derived with the original
Finnish valuation algorithm differed signiﬁcantly with respect to sex, age,
and education, just as they did using the Greek valuation system. In most
cases, the full range of possible responses has been used satisfactorily and
ﬂoor and ceiling effects were generally moderate. In general, internal
consistency reliability was also satisfactory.
Conclusion: The valuation system generated results demonstrating satis-
factory psychometric properties. Further research should validate the 15D
in the general Greek population.
Keywords: 15D, coronary artery disease, quality of life, validation,
valuation.
Introduction
Over the past years, it has become common practice to admin-
ister clinical trials with the use of measurement tools that evalu-
ate health-related quality of life (HRQoL). This development
reﬂects the acknowledgement that health depends not only on the
duration of life, but also on its quality. The need to establish new
methods for the evaluation of the effectiveness of medical prac-
tices is also triggered by the observed rapid increase of health
expenditure. Based on these, health systems strive for a more
rational allocation of resources. Thus, these new interdisciplinary
approaches are not limited to a static measurement using mor-
bidity and mortality indicators, but extend to analyses and mea-
surements of the clinical and social outcomes of therapy or a
surgical operation [1,2].
The HRQoL scores of some instruments can be employed to
compute the well-known Quality Adjusted Life Years (QALYs).
In brief, these constitute a measurement unit for the value of
therapeutic results, designed to compare dissimilar concepts
within the health sector and determine priorities. The method
allows researchers to calculate the consequences of health-care
interventions in nonmonetary terms. Their rationale is based on
an effort to combine quality of life with quantity of life, and their
main advantage lies in the fact that they can coevaluate the
beneﬁts from the reduction of morbidity (qualitative beneﬁts)
with those from the reduction of mortality (quantitative beneﬁts)
[3].
Cardiovascular diseases constitute the primary mortality and
disability cause, and have been responsible for 49% of all deaths
in Europe over the past years [2]. In the beginning of the 1960s,
Greece performed comparatively well regarding mortality indi-
cators for cardiovascular diseases, but since then, international
mortality charts show a disturbing rise in all indicators. This can
be mostly attributed to the change in dietary habits, the lack of
exercise, and the high percentage of smokers. Another distressing
fact is that, as Greece increasingly adopts western lifestyle, its
position in the chart concurrently deteriorates. The signiﬁcant
effect of cardiovascular diseases within the health-care system is
further emphasized by the fact that, on an annual basis, huge
economic resources are allocated to their management at a
national level [4].
Coronary artery disease (CAD) is a type of cardiovascular
condition affecting patients’ HRQoL through deterioration of
almost all functions. More speciﬁcally, it not only induces
changes to physical well-being, but also affects psychosocial
dimensions of life, daily activities, family and social relation-
ships, work, and leisure time. This implies that the HRQoL of
patients with CAD is affected along almost all its aspects. Hence,
the use of an instrument such as the 15D, which includes a
variety of dimensions and gives an overall view of a patient’s
condition, is necessary [5].
The aim of the present study was threefold: 1) to replicate,
using the Greek version of the 15D instrument, the three-stage
valuation procedure [6] using a sample of CAD patients; 2)
to investigate, on a preliminary basis, the psychometric
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properties—namely validity and reliability—of the instrument in
the Greek environment; and 3) to evaluate the HRQoL
of patients with CAD.
Methods
Patients
Ethical approval for the study came from hospital and regional
health system ofﬁcials. The generic instrument 15D was admin-
istered between October 2005 and May 2006 to consenting
consecutive CAD patients that were hospitalized in the cardiol-
ogy departments of one military and two National Health System
urban hospitals located in Athens, Serres, and Lamia, respec-
tively. The diagnosis was based on the clinical ﬁndings and the
supporting tests (i.e., electrocardiogram, stress test, and thallium
nuclear scan). These patients were not receiving drugs pertaining
to the disease and had not been subjected to interventional treat-
ment (coronary catheterization, balloon angioplasty), which
could have improved the clinical outcome. The 15D question-
naire was administered by face-to-face interviews from trained
investigators before the coronary catheterization to all eligible
patients. Nevertheless, only those with a positive result in the
examination were included in the study, with all others being
discarded. Among the former, a participation rate of 90.7% was
attained.
The sample consisted of 420 patients with CAD of whom 309
were men (73.6%) and 111 were women (26.4%). Regarding
age, 25.2% (106 people) were ages 50 to 59 years, 34.3% (144)
were ages 60 to 69 years, 31.7% (133) were ages 70 to 79 years,
and 8.8% (37) were ages 80 to 89 years. Overall, age ranged
from 51 to 87 years. Finally, in relation to education, 225 par-
ticipants (53.6%) had less than 9 years of education, 137 par-
ticipants (32.6%) had between 9 and 12 years of education, and
58 participants (13.8%) had over 12 years of education.
Description of the 15D
The 15D is an operationalization of the World Health Organi-
zation’s deﬁnition of health, the aim being to create a generic,
standardized, comprehensive, and multidimensional HRQoL
measurement instrument [6,7]. It was designed to measure
HRQoL and its changes in the general population or in speciﬁc
socioeconomic and cultural groups, as well as in patients suffer-
ing from various types of diseases, disorders, and disabilities
[8,9]. The instrument includes 15 dimensions: mobility, vision,
hearing, breathing, sleeping, eating, speech, elimination, usual
activities, mental function, discomfort and symptoms, depres-
sion, distress, vitality, and sexual activity. Each dimension is
divided into ﬁve possible response levels, hierarchically struc-
tured from the best to the worst possible health condition, meant
to capture the current status of a person’s health. Thus, the best
possible condition of an individual’s health is represented by level
1, the worst by level 5, although the rest describe intermediate
health conditions. The instrument also includes a system of pref-
erence weights, by which the responses to the dimensions are
converted into a single-index score on a 0 to 1 scale (1 corre-
sponds to full HRQoL, whereas 0 to death) [6,10].
The 15D questionnaire is relatively brief and easy to use as its
self-administration takes from 5 to 10 minutes [6]. In addition, it
has been shown to be a reliable, valid, acceptable, and responsive
instrument [1,10,11]. In particular, studies conducted with the
use of 15D in patients with heart problems, repeated after a
3-month interval, revealed an excellent reliability of the measure-
ment instrument, which was greater than that of another reliable
instrument, namely the Nottingham Health Proﬁle. At the same
time, similar studies revealed the instrument’s very high content
and construct validity and its satisfactory sensitivity [6]. A trans-
lation of the original English-language valuation questionnaire
and of the 15D instrument itself was performed after formal
procedures [12]. Two independent translations from English to
Greek were realized, followed by backward translations. A mul-
tidisciplinary expert panel resolved any differences between the
two translations and compared the ﬁnal outcome with an exist-
ing earlier translation of the 15D from prior research in the
Greek setting [13].
Valuation
The valuation system of the 15D is based on an application of the
multiattribute utility theory. In the present study, a single-index
score was calculated from the health state descriptive system by
using a set of preference or utility weights elicited from the
sample of CAD patients. The three-stage valuation procedure
was implemented and the utilities were used in an additive aggre-
gation formula to generate the single-index 15D score as follows
[6]:
V I x w x
j
j j j jH = ∑ ( ) ( )[ ] (1)
where Ij(xj) is the average relative importance people correspond
to various levels of dimension j (j = 1, 2, . . . , 15), and wj(xj) is
the average value that the respondents place on various levels of
dimension j.
One part of the sample was used to obtain the importance
weights. Speciﬁcally, a group of 300 patients were asked to
indicate the relative importance of each dimension from the
viewpoint of HRQoL on an adjacent 0 to 100 importance scale
by placing the dimension that is considered the most important at
the top (i.e., at 100). The values given to each dimension by all
the patients were averaged and transformed so that the sum of
weights was equal to 1. These importance weights were elicited
with respect to both the top and bottom level of each dimension,
and means (SDs) and 95% conﬁdence intervals (CIs) were
calculated.
To assign importance weights for the intermediate levels, we
extrapolated linearly from the extreme-end weights in relation to
the distance between level values [6]. The level values were
elicited similarly by using a 0 to 100 ratio scale and having the
remaining 120 patients place the most desirable level at 100. In
addition to the ﬁve levels, the states of being unconscious and
dead were also valued for each dimension. The individual values
given to a level were averaged and divided by 100 to obtain the
desirability value of that level. Therefore, the within-dimension
values reﬂect the distance between the levels on a 0 to 1 scale. To
obtain the preference weight for each level of a dimension, the
level value was multiplied by the importance weight of that
dimension.
Psychometric Properties
Thus far, the users of the 15D in different countries have applied
the Finnish (or Danish) valuations in their studies. In the present
study, the valuation was performed by a sample of Greek
patients, and it is therefore important to accumulate evidence to
support the sensitivity, reliability, and validity of the 15D utilities
derived from a Greek scoring algorithm. The sensitivity of the
15D measurement model was evaluated by examining: 1)
response distributions for each dimension to ensure that the full
range of possible responses was used; and 2) dimension ﬂoor and
ceiling effects to assess the ability of the items to capture the full
range of health states. Reliability of the instrument was estimated
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by examining correlations between each dimension and the scale
composed of the other dimensions (i.e., correction for overlap)
and via Cronbach’s alpha, both overall and with the item deleted
from the scale, to assess internal consistency reliability. In the ﬁrst
case, internal consistency is substantial and satisfactory when
correlation is at least 0.40 [14], whereas for Cronbach’s alpha
the 0.70 standard for group-level comparisons was adopted [15].
To assess construct validity, hypothesized relationships
between sociodemographic variables and HRQoL, which have
been previously reported in the literature, were examined. Spe-
ciﬁcally, it was expected that females, older subjects, and those
with a lower educational status would report lower HRQoL
[16,17]. As for the various self-reported clinical conditions,
which constitute risk factors for developing CAD, it has been
shown that diabetes and hypertension are associated with a
lower HRQoL [18,19], whereas hyperlipidemia appears not to
affect HRQoL [20,21].
Nevertheless, because the ﬁrst two conditions are asymptom-
atic, it is not justiﬁed to a priori assume HRQoL differences
between the blood pressure groups or groups at different choles-
terol levels before these risk factors materialize in the form of
e.g., myocardial infarction or stroke. Smoking status has also
been shown to affect HRQoL in some studies [16,22]. Neverthe-
less, the deﬁnition adopted in a study might be important,
because in this research we considered those who never smoked
as nonsmokers, whereas we classiﬁed all others as smokers (i.e.,
daily, occasional, and ex-smokers). The HRQoL scores were
calculated using the Greek and the original Finnish valuation
system. Taking into consideration the fact that a Greek 15D
valuation system has never been used before, the purpose of
comparing group scores to those derived from the original
Finnish valuation system was to rule out the possibility of
observed utility differences being a result of the new algorithm.
We hypothesized that if the pattern of results resembled that from
the original scoring algorithm, this could be taken as evidence
that score differences generated are indeed a valid representation
of the effect of various demographic and risk factors.
Statistical Analyses
Average importance weights were expressed as mean (SD) and
95% CIs. 15D utilities were examined with t-test and analysis of
variance, and utilities from the Greek and original Finnish
scoring algorithms were compared using the paired samples
t-test. Statistical signiﬁcance was assumed for P-values <0.05. All
data were analyzed using SPSS version 13.0.
Results
The 15D dimension descriptive statistics and item-scale reliabil-
ity analysis is presented in Table 1. For most of the dimensions,
responses were not clustered at the upper end of the scale (i.e.,
better health) and this was expected in a disease population. In
most cases, the full range of possible responses has been used,
satisfactorily supporting the overall sensitivity of the instru-
ment’s measurement model. Floor and ceiling effects were gen-
erally moderate implying that the 15D dimensions captured the
full range of health states. The most noteworthy ceiling effects
were observed on the dimensions of eating and speech, 80.7%
and 82.1%, respectively, which obviously implies reduced dis-
criminatory power for these particular dimensions, at least in this
patient group.
The 0.40 criterion for internal consistency was satisﬁed in all
cases, except for the dimension of distress, which did not corre-
late strongly with the rest of the scale (r = 0.228). Cronbach’s
alpha was estimated 0.835 with all items (dimensions) included,
which by far exceeds the 0.70 criterion for satisfactory internal
consistency reliability. Alpha was reduced (0.814 to 0.829) in 14
out of the 15 cases where one dimension was deleted from the
scale (Table 1), implying that each of these 14 particular dimen-
sions actually contribute to increasing the overall reliability of
the instrument and that they are actually measuring similar con-
structs. Only the exclusion of the distress dimension, which did
not previously satisfy the internal consistency criterion as well,
resulted in an improved Cronbach’s alpha, implying that its
presence decreases overall reliability.
The average importance weights were computed for the top
and bottom of each of the 15 dimensions, and their means, SDs,
and 95% CIs are presented in Table 2. At the top of the dimen-
sions, breathing normally was indicated by the subjects as the
most important health attribute, whereas the ability to have
normal sexual activity as the least important one. At the bottom
of the dimensions, respondents valued the lack of mobility as the
least desirable (lowest importance weight) health state and the
inability to have sexual activity as the most desirable (highest
importance weight) in relation to other unfavorable health states.
Although the processes of obtaining importance weights at the
top and bottom of the dimensions are identical, the average
Table 1 15D item descriptive statistics and item-scale reliability analysis
15D dimension Mean (SD) 95% CI Median
Response frequencies (%) Reliability analysis
1 2 3 4 5
Item-total
correlation
Alpha
(item deleted)
Mobility 2.18 (0.91) 2.09–2.26 2.00 27.1 34.3 33.1 4.8 0.7 0.402 0.829
Vision 1.66 (0.86) 1.57–1.74 1.00 55.7 27.1 12.9 4.3 — 0.448 0.826
Hearing 1.72 (0.85) 1.64–1.80 2.00 49.0 34.0 13.1 3.3 0.5 0.471 0.825
Breathing 2.60 (0.94) 2.51–2.69 3.00 11.2 37.1 34.0 16.0 1.7 0.584 0.817
Sleeping 1.89 (0.97) 1.80–1.99 2.00 43.8 31.4 17.1 6.9 0.7 0.468 0.825
Eating 1.31 (0.71) 1.24–1.37 1.00 80.7 10.7 5.7 2.9 — 0.435 0.827
Speech 1.22 (0.53) 1.17–1.22 1.00 82.1 14.4 3.1 0.2 0.2 0.447 0.828
Elimination 1.63 (0.77) 1.56–1.70 1.00 51.7 36.4 9.3 2.4 0.2 0.470 0.825
Usual activities 2.63 (1.08) 2.53–2.73 3.00 16.2 30.5 31.7 17.6 4.0 0.620 0.814
Mental function 1.69 (0.79) 1.61–1.77 2.00 48.1 37.6 11.7 2.4 0.2 0.468 0.825
Discomfort/symptoms 2.04 (0.84) 1.96–2.12 2.00 26.2 50.0 17.8 5.5 0.5 0.427 0.827
Depression 2.09 (0.99) 1.99–2.18 2.00 32.8 35.7 22.9 6.9 1.7 0.472 0.825
Distress 2.85 (1.06) 2.74–2.95 3.00 8.6 32.9 30.2 22.1 6.2 0.228 0.842
Vitality 2.43 (0.85) 2.35–2.51 2.00 9.3 51.4 27.4 10.7 1.2 0.489 0.823
Sexual activity 2.83 (1.01) 2.74–2.93 3.00 8.1 29.3 41.2 14.0 7.4 0.521 0.821
CI, conﬁdence interval.
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weights are—to some extent—different as would be expected.
This was veriﬁed in this study as only one dimension, vitality,
demonstrated similar top and bottom weights. In all other cases,
the differences were signiﬁcant (paired samples t-test P < 0.001).
These differences imply that, for example, lack of mobility
(inability to have sexual activity) is associated with greater (less)
utility loss than could be inferred from the importance weights of
these dimensions at the top.
The average value for each level and the importance weights
for intermediate levels are shown in Table 3 for each of the 15
dimensions. All values were calculated according to the method-
ology described previously, and form the basis of the ﬁrst Greek
scoring algorithm for the 15D. This algorithm was used to cal-
culate 15D utilities for the entire sample (N = 420) of CAD
patients participating in this study.
The mean utilities by demographic variables and risk factors
related to the disease are presented in Table 4. Regarding demo-
graphic variables, men, younger subjects, and those with more
years of education all had higher 15D scores (P < 0.001). These
results are meaningful in terms of assessing the HRQoL in this
disease group. Nevertheless, they also provide sound evidence to
support the validity of 15D utilities derived with a Greek valu-
ation system because all hypotheses concerning the expected
differences were conﬁrmed. In respect to various risk factors used
to form subgroups for comparisons, the 15D was apparently able
to discriminate between patients with and without diabetes, as
the latter expectedly scored borderline signiﬁcantly higher
(P = 0.054). On the other hand, no signiﬁcant differences
appeared in mean utilities of subjects with and without hyper-
tension and hyperlipidemia, or between smokers and non-
smokers. The same pattern of results was observed for both
demographic and risk factors, with the Finnish scoring system as
well, although the latter systematically produced lower scores
(paired samples t-test, P < 0.001).
Discussion
The purpose of this study was to perform a valuation of the
Greek 15D HRQoL instrument using a sample of 420 CAD
patients from three different hospitals, to assess the basic psy-
chometric properties such as sensitivity, reliability, and construct
validity of the Greek version, and subsequently to assess the
HRQoL of this patient group based on the values they themselves
placed on various dimensions of health. From a national perspec-
tive, this study adds to the recently increasing literature on
generic HRQoL instruments having demonstrated their validity
in the Greek environment such as the SF-36 [23,24], the SF-6D
[25], the SF-12 [26], and the EQ-5D [27,28]. Internationally,
Table 2 Average importance weights for the bottom and top of the 15D dimensions (N = 300)
Dimension
Top of dimension Bottom of dimension
P-value*Mean (SD) 95% CI Mean (SD) 95% CI
Mobility 0.074 (0.012) 0.073–0.075 0.028 (0.022) 0.025–0.030 <0.001
Vision 0.069 (0.017) 0.067–0.071 0.039 (0.027) 0.036–0.042 <0.001
Hearing 0.062 (0.014) 0.060–0.063 0.076 (0.031) 0.073–0.080 <0.001
Breathing 0.078 (0.013) 0.077–0.080 0.043 (0.033) 0.039–0.047 <0.001
Sleeping 0.065 (0.016) 0.063–0.067 0.073 (0.032) 0.069–0.076 <0.001
Eating 0.070 (0.014) 0.068–0.071 0.048 (0.029) 0.045–0.051 <0.001
Speech 0.063 (0.012) 0.062–0.064 0.077 (0.029) 0.074–0.080 <0.001
Elimination 0.059 (0.015) 0.057–0.061 0.070 (0.033) 0.066–0.074 <0.001
Usual activities 0.070 (0.014) 0.069–0.072 0.078 (0.031) 0.074–0.081 <0.001
Mental function 0.070 (0.013) 0.069–0.071 0.063 (0.032) 0.059–0.066 <0.001
Discomfort/symptoms 0.069 (0.014) 0.067–0.071 0.052 (0.034) 0.048–0.056 <0.001
Depression 0.061 (0.015) 0.060–0.063 0.076 (0.037) 0.072–0.080 <0.001
Distress 0.059 (0.013) 0.058–0.061 0.091 (0.027) 0.087–0.094 <0.001
Vitality 0.075 (0.013) 0.074–0.077 0.077 (0.032) 0.073–0.081 0.406
Sexual activity 0.055 (0.014) 0.054–0.057 0.110 (0.038) 0.106–0.114 <0.001
*Mean weights compared with paired-samples t-test.
CI, conﬁdence interval.
Table 3 Average values and level importance weights for each 15D dimension (N = 120)
Dimension
Average value for each level [Wj(Xj)] Level importance weight (Ij)
1 2 3 4 5 Uncon Dead 1 2 3 4 5
Mobility 1.000 0.692 0.541 0.390 0.227 0.120 0.000 0.074 0.056 0.047 0.038 0.028
Vision 1.000 0.724 0.567 0.405 0.233 0.104 0.000 0.069 0.058 0.052 0.046 0.039
Hearing 1.000 0.725 0.567 0.416 0.263 0.136 0.000 0.062 0.067 0.070 0.073 0.076
Breathing 1.000 0.651 0.510 0.377 0.240 0.115 0.000 0.078 0.062 0.055 0.049 0.043
Sleeping 1.000 0.705 0.560 0.408 0.260 0.121 0.000 0.065 0.068 0.070 0.071 0.073
Eating 1.000 0.670 0.538 0.376 0.232 0.109 0.000 0.070 0.060 0.057 0.052 0.048
Speech 1.000 0.689 0.534 0.400 0.268 0.137 0.000 0.063 0.069 0.072 0.075 0.077
Elimination 1.000 0.681 0.526 0.285 0.246 0.120 0.000 0.059 0.064 0.066 0.068 0.070
Usual activities 1.000 0.680 0.519 0.373 0.242 0.114 0.000 0.070 0.074 0.075 0.077 0.078
Mental function 1.000 0.678 0.520 0.393 0.253 0.118 0.000 0.070 0.067 0.065 0.064 0.063
Discomfort/symptoms 1.000 0.697 0.540 0.407 0.267 0.116 0.000 0.069 0.062 0.058 0.055 0.052
Depression 1.000 0.697 0.534 0.394 0.254 0.102 0.000 0.061 0.067 0.070 0.073 0.076
Distress 1.000 0.710 0.572 0.413 0.295 0.137 0.000 0.059 0.072 0.078 0.085 0.091
Vitality 1.000 0.718 0.581 0.424 0.280 0.136 0.000 0.075 0.076 0.076 0.077 0.077
Sexual activity 1.000 0.686 0.521 0.367 0.236 0.113 0.000 0.055 0.078 0.090 0.101 0.110
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it could contribute to cross-country comparisons of results from
HRQoL studies involving CAD patients.
Previous studies have addressed the psychometric properties
of 15D scores generated with the weights from the original
(Finnish) valuation system [29,30], and have produced remark-
able results. Furthermore, other studies have addressed the trans-
lation and cultural adaptation of the 15D instrument in different
countries [13,31]. The present study is one of the few to address
validity and reliability of 15D scores generated from a valuation
procedure performed by a national sample, and speciﬁcally, a
group of Greek CAD patients. In this respect, it is expected to
contribute to the growing body of knowledge on HRQoL mea-
surement with multiattribute utility instruments.
The results reported here indicate that the Greek version of
the 15D instrument demonstrates satisfactory sensitivity, reliabil-
ity, and construct validity, on the basis of the valuation per-
formed by a sample of patients with CAD. It discriminates well
between subgroups varying in sociodemographic factors, sup-
porting what is known as “known-groups” construct validity
[15]. Concerning risk factors, only subgroups with and without
diabetes demonstrated signiﬁcantly different 15D utilities,
whereas insigniﬁcant differences were observed in subgroups
with and without hypertension and hyperlipidemia. Perhaps the
latter was to be expected because these risk factors are generally
not associated with pain, discomfort, or other symptoms, which
could result in a deﬁcit of HRQoL.
To increase the certainty that it was the nature of the risk
factors considered and not the valuation procedure, which was
“at fault” for the apparently poor inability of the instrument to
differentiate between clinical conditions, mean utilities were also
calculated for all subgroups, using the original Finnish valuation
algorithm. Expectedly, no differences were observed. The 15D
utilities derived with the original valuation algorithm differed
signiﬁcantly (P < 0.001) with respect to sex, age, and education,
just as they did using the Greek valuation system. By means of
the Finnish valuation system, scores were again not different
between the subgroups with and without the risk factors (again
with the exception of diabetes).
It is also worth mentioning that the Greek valuation system-
atically generated higher 15D utilities than the Finnish one
(paired samples t-test, P < 0.001). A possible explanation could
be that this Greek sample apparently placed higher values on
dimensions in which they subsequently scored higher (i.e., result-
ing in higher overall utilities). Another reason could be that a
disease group performed the Greek valuation, whereas the origi-
nal Finnish system was derived from a general population. A
possible explanation in this case could be that patients with
impaired HRQoL may have overvalued health states, which are
generally taken for granted by the “healthy” general population.
It should be noted that the prevalence of CAD is higher in
men than in women, and the majority of HRQoL studies from
different countries involving this particular disease population
have reported dominating (>70%) proportions of male subjects
[32–34]. It has been well recognized that important differences
exist between women and men with regard to the function and
progression of diseases of the cardiovascular system [35], with
more positive outcomes—and hence HRQoL—corresponding to
males. The present study, using a representative sample of the
Greek CAD population, is primarily a valuation study, and to a
lesser extent, a HRQoL study. The sex disproportion (73.6%
males) is not expected to affect the results because the produced
15D scoring algorithm was used on the sample from which it was
derived. This does not imply that it should not be used with other
samples and populations, in which case however extensive vali-
dation exercises must be performed.
This study also has some limitations. Although cross-
sectional construct validity, as well as internal consistency reli-
ability and sensitivity of the Greek 15D have been fairly
demonstrated, other issues such as test–retest reliability, longitu-
dinal construct validity, and responsiveness have not been
addressed. This is particularly important as health status changes
over time and it is necessary for the instrument to be able
to detect these changes, particularly those of clinical importance.
Moreover, it should be noted that the clinical conditions consti-
tuting the risk factors were self-reported and it has been shown
that the reliance on such data may result in biased estimates of
the prevalence of some conditions [36]. Moreover, signiﬁcant
differences have been found between self-reported and measured
anthropometric indices in Greek study participants [37]. Regard-
ing hypertension, 39% of Greeks suffering from the condition are
actually unaware of their health problem [38].
Conclusion
This was the ﬁrst study in which a scoring algorithm was derived
for the Greek version of the 15D instrument, based on valuations
placed on the health states by a sample of CAD patients. The
valuation system generated results demonstrating satisfactory
reliability and validity, as well as comparability to the original
Finnish scoring system. Future efforts might be focused on deriv-
ing a valuation system from a larger sample from the Greek
Table 4 Mean 15D scores from Greek and Finnish valuations by demo-
graphic variables and CAD risk factors
Variable N (%)
15D Score
P-value‡
Greek
valuation
Finnish
valuation
Demographics
Sex
Male 309 (73.6) 0.764 0.746 <0.001
Female 111 (26.4) 0.706 0.669 <0.001
P-value* <0.001 <0.001
Age (years)
50–59 106 (25.2) 0.831 0.821 <0.001
60–69 144 (34.3) 0.752 0.730 <0.001
70–79 133 (31.7) 0.720 0.694 <0.001
80–89 37 (8.8) 0.598 0.550 <0.001
P-value† <0.001 <0.001
Education
<9 years 225 (53.6) 0.723 0.697 <0.001
9–12 years 137 (32.6) 0.771 0.752 <0.001
>12 years 58 (13.8) 0.793 0.779 <0.001
P-value† <0.001 <0.001
Risk factors
Smoking
Yes 221 (52.6) 0.752 0.733 <0.001
No 199 (47.4) 0.744 0.718 <0.001
P-value* 0.469 0.262
Hypertension
Yes 197 (46.9) 0.747 0.721 <0.001
No 223 (53.1) 0.749 0.730 <0.001
P-value* 0.869 0.468
Hyperlipidemia
Yes 169 (40.2) 0.746 0.721 <0.001
No 251 (59.8) 0.750 0.729 <0.001
P-value* 0.671 0.554
Diabetes
Yes 129 (30.7) 0.733 0.704 <0.001
No 291 (69.3) 0.755 0.736 <0.001
P-value* 0.054 <0.05
*Mean 15D scores by sex and risk factors compared with t-tests.
†Mean 15D scores by age and education compared with ANOVA.
‡Mean 15D scores from Greek and original Finnish valuation compared with paired-samples
t-tests.
CAD, coronary artery disease.
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general population, which would contribute even more toward
cross-cultural HRQoL comparisons using the instrument.
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